Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2007

Barthold SW, Borowsky AD, Brayton C, Bronson R, Cardiff RD, Griffey SM, et al. From whence will they come? - A perspective on the acute shortage of pathologists in biomedical research. J Vet Diagn Invest. 2007;19(4):455-6.

Magro CM, Schaefer JT, A Crowson N, Li J, Morrison C. Pigmented purpuric dermatosis: classification by phenotypic and molecular profiles. Am J Clin Pathol. 2007;128(2):218-29.

Magro CM, A Crowson N, Morrison C, Li J. Pityriasis lichenoides chronica: stratification by molecular and phenotypic profile. Hum Pathol. 2007;38(3):479-90.

Mitchell JE, Oshima T, Piper SE, Webster CL, Westblade LF, Karimova G, et al. The Escherichia coli regulator of sigma 70 protein, Rsd, can up-regulate some stress-dependent promoters by sequestering sigma 70. J Bacteriol. 2007;189(9):3489-95.

Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, et al. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007;9(4):441-51.

Lamant L, de Reyniès A, Duplantier M-, Rickman DS, Sabourdy F, Giuriato S, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156-64.

Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39(3):347-51.

Ouseph MM, Sharan GK, Sharma P, Rathi AK, Shyama J, Singh K, et al. Osteosarcoma with cutaneous metastases. A case report. Acta Cytol. 2007;51(1):102-6.

Ali S, Cohen C, Little JV, Sequeira JH, Mosunjac MB, Siddiqui MT. The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors. Diagn Cytopathol. 2007;35(10):644-8.

Mones JV, Coleman M, Kostakoglu L, Furman RR, Chadburn A, Shore TB, et al. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leuk Lymphoma. 2007;48(2):342-8.